HMNC Brain Health’s pipeline consists of two late-stage derisked assets in development for difficult-to-treat depression.

• The Ketabon program, partnered with MEDICE for European commercialization, is an oral prolonged-release formulation of ketamine for Treatment-Resistant Depression (TRD), designed for at-home use, with the potential to offer short time to remission, with lower side effects compared to existing IV or intranasal ketamine treatments.
• The Nelivabon program is a first-in-class oral vasopressin V1b receptor antagonist targeting the human body’s stress axis (HPA-axis) with potential in adjunct treatment of MDD, positioned before the use of add-on antipsychotics.

HMNC Brain Health is set to flexibly grow and commercialize its portfolio via in-house developments as well as in- and out-licensing agreements.